Octreotid Sun (Octreotide)

Octreotide, the active ingredient in Octreotid Sun, is a peptide hormone somatostatin analog presented as a strength/form for injection use. It is employed in the management of certain hormonal disorders and tumor-related conditions in adults.

GNH USA supplies Octreotid Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Octreotide is a synthetic analogue of somatostatin that modulates neuroendocrine activity in several disease pathways.

- Acromegaly: reduces growth hormone and IGF‑1 levels, helping control disease activity. - Neuroendocrine tumors (carcinoid syndrome): alleviates flushing and diarrhoea associated with hormone secretion. - Variceal bleeding prophylaxis: lowers portal pressure and reduces risk of re‑bleeding. - Severe hypoglycaemia: suppresses insulin release in patients with refractory hypoglycaemia. - Diagnostic imaging: enhances contrast of somatostatin‑receptor positive lesions during scintigraphy.

Adverse reactions to octreotide are generally dose‑related and may vary with the route of administration.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal cramping, or diarrhoea. - Injection site reactions: erythema, pain or induration. - Gallbladder changes: biliary sludge or gallstones. - Metabolic alterations: hyperglycaemia or hypoglycaemia. - Headache or fatigue.

Serious or Rare Side Effects: - Pancreatitis. - Severe hyperglycaemia requiring insulin therapy. - Acute cholecystitis. - Cardiac arrhythmias. - Anaphylactic‑type reactions. - Severe injection‑site infection.

Octreotide should be used only under medical supervision, with attention to patient‑specific factors and monitoring requirements.

- Renal impairment: dose may need adjustment and renal function should be monitored. - Hepatic dysfunction: use caution and assess liver enzymes regularly. - Diabetes mellitus: monitor blood glucose closely as the drug can affect glycaemic control. - Gallbladder disease: patients with a history of gallstones should be evaluated before therapy. - Pregnancy and lactation: only use if the potential benefit outweighs potential risk to fetus or infant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octreotide may interact with several medicines, altering either its efficacy or the effect of the co‑administered drug.

Major Interactions (Avoid): - Cytochrome P450 inducers: carbamazepine, rifampicin – may reduce octreotide plasma levels. - Long‑acting somatostatin analogues: concurrent use can increase risk of gallbladder complications.

Moderate Interactions (Monitor Closely): - Insulin and oral hypoglycaics: octreotide can blunt insulin secretion, requiring dose adjustments. - Antiplatelet agents: may increase bleeding time when used with octreotide for variceal bleeding prophylaxis. - Diuret‑s‑for‑heart ​   ---